Type I interferons in systemic autoimmunity

Silvano Sozzani, Daniela Bosisio, Mirko Scarsi, Angela Tincani

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Type I IFN (IFN-I) was firstly described in 1957 as a soluble factor responsible for viral resistance in vitro. Today, it is well known that the IFN-I family comprises a wide number of cytokines with different modulatory effects on angiogenesis, cell growth, fibrosis, and apoptosis. However, one of the most important functions of IFN-I is the capability to trigger a complex array of cellular responses that result in a host-protective antiviral response. For this reason, IFN-I can be considered a ?director? of protective immune responses. The recent finding of the so-called interferon signature in patients suffering from different autoimmune diseases has underlined its possible role in the pathogenesis of these diseases. On the other hand, IFN-a/b is reported to be efficacious in the treatment of some autoimmune and infectious diseases not responsive to conventional therapy. On these occasions, the treated patients often start or increase autoantibody production supporting the role of IFN as inducer of an autoimmune response. In this review, we will underline recent acquisitions about IFN-I biology, with a focus on the relevance of the induction of some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, dermato/polymiositis, and Sjogren's syndrome.

Original languageEnglish
Pages (from-to)196-203
Number of pages8
JournalAutoimmunity
Volume43
Issue number3
DOIs
Publication statusPublished - May 2010

Fingerprint

Interferon Type I
Autoimmunity
Autoimmune Diseases
Systemic Scleroderma
Sjogren's Syndrome
Systemic Lupus Erythematosus
Autoantibodies
Interferons
Antiviral Agents
Communicable Diseases
Rheumatoid Arthritis
Fibrosis
Apoptosis
Cytokines
Therapeutics
Growth

Keywords

  • Autoimmunity
  • Cytokines
  • Plasmacytoid dendritic cells
  • Type I IFN

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Type I interferons in systemic autoimmunity. / Sozzani, Silvano; Bosisio, Daniela; Scarsi, Mirko; Tincani, Angela.

In: Autoimmunity, Vol. 43, No. 3, 05.2010, p. 196-203.

Research output: Contribution to journalArticle

Sozzani, S, Bosisio, D, Scarsi, M & Tincani, A 2010, 'Type I interferons in systemic autoimmunity', Autoimmunity, vol. 43, no. 3, pp. 196-203. https://doi.org/10.3109/08916930903510872
Sozzani, Silvano ; Bosisio, Daniela ; Scarsi, Mirko ; Tincani, Angela. / Type I interferons in systemic autoimmunity. In: Autoimmunity. 2010 ; Vol. 43, No. 3. pp. 196-203.
@article{6aaa4ef61cdf4b32989c89c4c360352b,
title = "Type I interferons in systemic autoimmunity",
abstract = "Type I IFN (IFN-I) was firstly described in 1957 as a soluble factor responsible for viral resistance in vitro. Today, it is well known that the IFN-I family comprises a wide number of cytokines with different modulatory effects on angiogenesis, cell growth, fibrosis, and apoptosis. However, one of the most important functions of IFN-I is the capability to trigger a complex array of cellular responses that result in a host-protective antiviral response. For this reason, IFN-I can be considered a ?director? of protective immune responses. The recent finding of the so-called interferon signature in patients suffering from different autoimmune diseases has underlined its possible role in the pathogenesis of these diseases. On the other hand, IFN-a/b is reported to be efficacious in the treatment of some autoimmune and infectious diseases not responsive to conventional therapy. On these occasions, the treated patients often start or increase autoantibody production supporting the role of IFN as inducer of an autoimmune response. In this review, we will underline recent acquisitions about IFN-I biology, with a focus on the relevance of the induction of some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, dermato/polymiositis, and Sjogren's syndrome.",
keywords = "Autoimmunity, Cytokines, Plasmacytoid dendritic cells, Type I IFN",
author = "Silvano Sozzani and Daniela Bosisio and Mirko Scarsi and Angela Tincani",
year = "2010",
month = "5",
doi = "10.3109/08916930903510872",
language = "English",
volume = "43",
pages = "196--203",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Type I interferons in systemic autoimmunity

AU - Sozzani, Silvano

AU - Bosisio, Daniela

AU - Scarsi, Mirko

AU - Tincani, Angela

PY - 2010/5

Y1 - 2010/5

N2 - Type I IFN (IFN-I) was firstly described in 1957 as a soluble factor responsible for viral resistance in vitro. Today, it is well known that the IFN-I family comprises a wide number of cytokines with different modulatory effects on angiogenesis, cell growth, fibrosis, and apoptosis. However, one of the most important functions of IFN-I is the capability to trigger a complex array of cellular responses that result in a host-protective antiviral response. For this reason, IFN-I can be considered a ?director? of protective immune responses. The recent finding of the so-called interferon signature in patients suffering from different autoimmune diseases has underlined its possible role in the pathogenesis of these diseases. On the other hand, IFN-a/b is reported to be efficacious in the treatment of some autoimmune and infectious diseases not responsive to conventional therapy. On these occasions, the treated patients often start or increase autoantibody production supporting the role of IFN as inducer of an autoimmune response. In this review, we will underline recent acquisitions about IFN-I biology, with a focus on the relevance of the induction of some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, dermato/polymiositis, and Sjogren's syndrome.

AB - Type I IFN (IFN-I) was firstly described in 1957 as a soluble factor responsible for viral resistance in vitro. Today, it is well known that the IFN-I family comprises a wide number of cytokines with different modulatory effects on angiogenesis, cell growth, fibrosis, and apoptosis. However, one of the most important functions of IFN-I is the capability to trigger a complex array of cellular responses that result in a host-protective antiviral response. For this reason, IFN-I can be considered a ?director? of protective immune responses. The recent finding of the so-called interferon signature in patients suffering from different autoimmune diseases has underlined its possible role in the pathogenesis of these diseases. On the other hand, IFN-a/b is reported to be efficacious in the treatment of some autoimmune and infectious diseases not responsive to conventional therapy. On these occasions, the treated patients often start or increase autoantibody production supporting the role of IFN as inducer of an autoimmune response. In this review, we will underline recent acquisitions about IFN-I biology, with a focus on the relevance of the induction of some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, dermato/polymiositis, and Sjogren's syndrome.

KW - Autoimmunity

KW - Cytokines

KW - Plasmacytoid dendritic cells

KW - Type I IFN

UR - http://www.scopus.com/inward/record.url?scp=77951463979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951463979&partnerID=8YFLogxK

U2 - 10.3109/08916930903510872

DO - 10.3109/08916930903510872

M3 - Article

C2 - 20298124

AN - SCOPUS:77951463979

VL - 43

SP - 196

EP - 203

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 3

ER -